The µ-opioid system in midline thalamic nuclei modulates defence strategies towards a conditioned fear stimulus in male mice.


Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 21 7 2020
medline: 5 11 2021
entrez: 21 7 2020
Statut: ppublish

Résumé

Nuclei located in the dorsal midline thalamus, such as the paraventricular nucleus of the thalamus (PVT), are crucial to modulate fear and aversive behaviour. In addition, the PVT shows a dense expression of µ-opioid receptors (MORs) and could mediate the anxiolytic effects of opioids. We analysed the contribution of MORs in the dorsal midline thalamus (i.e. the PVT) to the performance of mice in a classical fear conditioning paradigm. We locally injected a specific agonist (DAMGO), an antagonist (CTAP) of MOR or saline as a control into the dorsal midline thalamus of male mice, prior to fear extinction training. We assessed freezing as a typical measure of fear and extended our analysis by evaluation of aversive, non-aversive and neutral behavioural features using compositional data analysis. Pharmacological blockade of MORs through CTAP in the dorsal midline thalamus induced a fear memory extinction deficit, as evidenced by maintained freezing during extinction sessions. Stimulation of MORs by DAMGO resulted in an overall increase in locomotor activity, associated with decreased freezing during recall of extinction. Compositional data analysis confirmed the freezing-related pharmacological effects and revealed specific differences in basic behavioural states. CTAP-treated mice remained in an aversive state, whereas DAMGO-treated mice displayed predominantly neutral behaviour. Fear extinction requires the integrity of the µ-opioid system in the dorsal midline thalamus. Pharmacological stimulation of MOR and associated facilitation of fear extinction recall suggest a potential therapeutic avenue for stress-related or anxiety disorders.

Sections du résumé

BACKGROUND
Nuclei located in the dorsal midline thalamus, such as the paraventricular nucleus of the thalamus (PVT), are crucial to modulate fear and aversive behaviour. In addition, the PVT shows a dense expression of µ-opioid receptors (MORs) and could mediate the anxiolytic effects of opioids.
METHODS
We analysed the contribution of MORs in the dorsal midline thalamus (i.e. the PVT) to the performance of mice in a classical fear conditioning paradigm. We locally injected a specific agonist (DAMGO), an antagonist (CTAP) of MOR or saline as a control into the dorsal midline thalamus of male mice, prior to fear extinction training. We assessed freezing as a typical measure of fear and extended our analysis by evaluation of aversive, non-aversive and neutral behavioural features using compositional data analysis.
RESULTS
Pharmacological blockade of MORs through CTAP in the dorsal midline thalamus induced a fear memory extinction deficit, as evidenced by maintained freezing during extinction sessions. Stimulation of MORs by DAMGO resulted in an overall increase in locomotor activity, associated with decreased freezing during recall of extinction. Compositional data analysis confirmed the freezing-related pharmacological effects and revealed specific differences in basic behavioural states. CTAP-treated mice remained in an aversive state, whereas DAMGO-treated mice displayed predominantly neutral behaviour.
CONCLUSIONS
Fear extinction requires the integrity of the µ-opioid system in the dorsal midline thalamus. Pharmacological stimulation of MOR and associated facilitation of fear extinction recall suggest a potential therapeutic avenue for stress-related or anxiety disorders.

Identifiants

pubmed: 32684084
doi: 10.1177/0269881120940919
pmc: PMC7604929
doi:

Substances chimiques

Narcotic Antagonists 0
Peptides 0
Receptors, Opioid, mu 0
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- 100929-53-1
connective tissue-activating peptide 69344-77-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1280-1288

Références

Front Behav Neurosci. 2016 Oct 04;10:185
pubmed: 27757077
Biol Psychiatry. 2009 Mar 1;65(5):438-40
pubmed: 19058787
J Anxiety Disord. 2007;21(1):142-52
pubmed: 16647240
Neuropharmacology. 2012 Jan;62(1):457-63
pubmed: 21903111
Behav Brain Res. 2003 Oct 17;145(1-2):89-98
pubmed: 14529808
Mol Psychiatry. 2020 Feb;25(2):428-441
pubmed: 29904149
Nature. 2015 Mar 26;519(7544):455-9
pubmed: 25600269
Nature. 2015 Mar 26;519(7544):460-3
pubmed: 25600268
Science. 2018 Oct 26;362(6413):423-429
pubmed: 30361366
Nature. 2016 Feb 11;530(7589):219-22
pubmed: 26840481
Neuropsychopharmacology. 2012 Jun;37(7):1588-99
pubmed: 22298122
Behav Neurosci. 2006 Apr;120(2):313-23
pubmed: 16719696
Neuron. 2008 Jul 31;59(2):298-310
pubmed: 18667157
J Psychopharmacol. 2011 Nov;25(11):1415-33
pubmed: 20530588
J Pharmacol Exp Ther. 2001 Jul;298(1):57-61
pubmed: 11408525
Learn Mem. 2015 Aug 18;22(9):417-25
pubmed: 26286652
N Engl J Med. 2010 Jan 14;362(2):110-7
pubmed: 20071700
Neurosci Biobehav Rev. 2015 Apr;51:138-50
pubmed: 25636946
Learn Mem. 2009 Feb 17;16(3):161-6
pubmed: 19223599
Neuropharmacology. 2007 Jun;52(8):1580-5
pubmed: 17445843
Learn Mem. 2007 Apr 10;14(4):313-7
pubmed: 17522020
Front Behav Neurosci. 2014 Mar 20;8:94
pubmed: 24688461
Behav Neurosci. 2005 Dec;119(6):1672-7
pubmed: 16420170
Sci Rep. 2019 Nov 28;9(1):17837
pubmed: 31780740
Neuropsychopharmacology. 2016 Dec;41(13):3092-3102
pubmed: 27417516
Psychopharmacology (Berl). 2009 Jul;204(4):599-606
pubmed: 19242678
J Consult Clin Psychol. 1991 Jun;59(3):425-30
pubmed: 1677015
Behav Neurosci. 2005 Aug;119(4):1023-33
pubmed: 16187830
J Neurosci. 1998 Mar 1;18(5):1671-8
pubmed: 9464992
Pharmacol Biochem Behav. 2013 Jan;103(3):672-7
pubmed: 23159544
Psychopharmacology (Berl). 1997 May;131(2):115-22
pubmed: 9201798
J Neurosci. 2018 Mar 7;38(10):2569-2578
pubmed: 29437889
Neurosci Biobehav Rev. 2015 Sep;56:315-29
pubmed: 26255593
J Neurosci. 2012 Sep 12;32(37):12651-6
pubmed: 22972990
Front Behav Neurosci. 2014 Mar 14;8:79
pubmed: 24672443
J Neurosci Methods. 2016 Sep 15;271:154-9
pubmed: 27450923
Neurosci Lett. 2015 Nov 16;609:92-6
pubmed: 26475506
Trends Neurosci. 2013 Jun;36(6):343-52
pubmed: 23602194

Auteurs

Xabier Bengoetxea (X)

Institute of Physiology I, University of Münster, Münster, Germany.

Lena Goedecke (L)

Institute of Physiology I, University of Münster, Münster, Germany.

Peter Blaesse (P)

Institute of Physiology I, University of Münster, Münster, Germany.

Hans-Christian Pape (HC)

Institute of Physiology I, University of Münster, Münster, Germany.

Kay Jüngling (K)

Institute of Physiology I, University of Münster, Münster, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH